These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27278809)

  • 1. Correction to "1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases.".
    J Pharmacol Exp Ther; 2016 Jul; 358(1):1-2. PubMed ID: 27278809
    [No Abstract]   [Full Text] [Related]  

  • 2. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
    Shin JM; Inatomi N; Munson K; Strugatsky D; Tokhtaeva E; Vagin O; Sachs G
    J Pharmacol Exp Ther; 2011 Nov; 339(2):412-20. PubMed ID: 21828261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
    Arikawa Y; Nishida H; Kurasawa O; Hasuoka A; Hirase K; Inatomi N; Hori Y; Matsukawa J; Imanishi A; Kondo M; Tarui N; Hamada T; Takagi T; Takeuchi T; Kajino M
    J Med Chem; 2012 May; 55(9):4446-56. PubMed ID: 22512618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening of potassium-competitive acid blockers.
    Kondo M; Kawamoto M; Hasuoka A; Kajino M; Inatomi N; Tarui N
    J Biomol Screen; 2012 Feb; 17(2):177-82. PubMed ID: 21940711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.
    Matsukawa J; Hori Y; Nishida H; Kajino M; Inatomi N
    Biochem Pharmacol; 2011 May; 81(9):1145-51. PubMed ID: 21371447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
    Gao T; Liu Y; Ji Y; Wu X; Xu J
    J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.
    Yamasaki H; Kawaguchi N; Nonaka M; Takahashi J; Morohashi A; Hirabayashi H; Moriwaki T; Asahi S
    Xenobiotica; 2017 Dec; 47(12):1027-1034. PubMed ID: 27414183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate.
    Liu L; Cao N; Ma X; Xiong K; Sun L; Zou Q
    J Sep Sci; 2016 Apr; 39(7):1232-41. PubMed ID: 26843471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pyrazole derivative 5-[1-(4-fluorophenyl)-1H-pyrazol-4-yl]-2H-tetrazole: synthesis and assessment of some biological activities.
    de Oliveira LP; da Silva DP; Florentino IF; Fajemiroye JO; de Oliveira TS; Marcelino RI; Pazini F; Lião LM; Ghedini PC; de Moura SS; Valadares MC; de Carvalho VV; Vaz BG; Menegatti R; Costa EA
    Chem Biol Drug Des; 2017 Jan; 89(1):124-135. PubMed ID: 27526659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
    Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
    Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
    Kogame A; Takeuchi T; Nonaka M; Yamasaki H; Kawaguchi N; Bernards A; Tagawa Y; Morohashi A; Kondo T; Moriwaki T; Asahi S
    Xenobiotica; 2017 Mar; 47(3):255-266. PubMed ID: 27225050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
    Di Santo R; Tafi A; Costi R; Botta M; Artico M; Corelli F; Forte M; Caporuscio F; Angiolella L; Palamara AT
    J Med Chem; 2005 Aug; 48(16):5140-53. PubMed ID: 16078834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro.
    Tramontano E; Esposito F; Badas R; Di Santo R; Costi R; La Colla P
    Antiviral Res; 2005 Feb; 65(2):117-24. PubMed ID: 15708638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
    Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
    J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
    J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
    Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
    Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.